Angela Kong

Placeholder Person Graphic
Received a BS and MS in materials science and engineering from Shanghai Jiao Tong University, an MS in chemical engineering and materials science from Wayne State University, and an MS in regulatory affairs and quality assurance from Temple University. She has 15 years of experience in the pharmaceutical industry and is currently a Principle Scientist in Pfi zer’s drug product development group. Her responsibilities include formulation and process development. Her primary interests are powder segregation, scale-up, technology transfer, and regulatory science. Angela has authored portions of multiple new drug applications, contributing to successful regulatory submissions and the launch of several new drug products. Prior to joining Pfizer, Angela worked for 8 years in the automotive industry.

Related Articles

Interpretation of Variance Components for Blend and Content Uniformity
Technical
Interpretation of Variance Components for Blend and Content Uniformity

Despite introducing modern analytical technology to assess blend uniformity, many companies are still using traditional blend sampling thieves and wet chemistry to assess blend homogeneity. The use of statistically based sampling plans allows variance component analysis to be conducted on both blend and dosage unit data. This article shows how various combinations of blend and dosage unit...